TRVI
Trevi Therapeutics, Inc. · Healthcare
Chief Scientific Officer Thomas Sciascia sold $87K of Trevi Therapeutics, Inc.
Sold$87,228
$2.77Price
31,505Shares
−13%Stake
What TRVI did after the filing
- The stock from Fri, Aug 16 close, $2.77
- +20.6%
- S&P 500, same days
- +3.8%
Measured over 30 trading days, to the Sep 30 close.
Traded Wed, Aug 14. Filed Fri, Aug 16, 12:47 PM ET, during the session. Returns use the Aug 16 close and the Sep 30 close. Not investment advice.